Kalaris Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Kalaris Therapeutics Stock-Based Compensation Growth & History (KLRS)
Kalaris Therapeutics's stock-based compensation was $1.9M for fiscal 2025.
View full Kalaris Therapeutics company overviewKalaris Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.9M | $1.0M | +116.31% |
| 2024 | 2024-12-31 | $895,000 | −$39.9M | −97.81% |
| 2023 | 2023-12-31 | $40.8M | −$536,000 | −1.30% |
| 2022 | 2022-12-31 | $41.3M | −$2.7M | −6.05% |
| 2021 | 2021-12-31 | $44.0M | $34.5M | +366.38% |
| 2020 | 2020-12-31 | $9.4M | $6.5M | +226.26% |
| 2019 | 2019-12-31 | $2.9M | — | — |
Kalaris Therapeutics quarterly stock-based compensation
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $644,000 | $53,000 | +8.97% |
| Q1 2026 | 2026-03-31 | $580,000 | $206,000 | +55.08% |
| Q4 2025 | 2025-12-31 | $333,000 | — | — |
| Q3 2025 | 2025-09-30 | $638,000 | $376,000 | +143.51% |
| Q2 2025 | 2025-06-30 | $591,000 | $269,000 | +83.54% |
| Q1 2025 | 2025-03-31 | $374,000 | −$4.7M | −92.57% |
| Q3 2024 | 2024-09-30 | $262,000 | −$10.2M | −97.50% |
| Q2 2024 | 2024-06-30 | $322,000 | −$10.0M | −96.87% |
| Q1 2024 | 2024-03-31 | $5.0M | −$5.0M | −49.81% |
| Q4 2023 | 2023-12-31 | $10.0M | $952,000 | +10.53% |
| Q3 2023 | 2023-09-30 | $10.5M | −$387,000 | −3.57% |
| Q2 2023 | 2023-06-30 | $10.3M | −$663,000 | −6.05% |
| Q1 2023 | 2023-03-31 | $10.0M | −$438,000 | −4.18% |
| Q4 2022 | 2022-12-31 | $9.0M | −$6.8M | −42.99% |
| Q3 2022 | 2022-09-30 | $10.9M | $569,000 | +5.53% |
| Q2 2022 | 2022-06-30 | $11.0M | $1.2M | +12.60% |
| Q1 2022 | 2022-03-31 | $10.5M | $2.4M | +29.17% |
| Q4 2021 | 2021-12-31 | $15.9M | $11.4M | +257.93% |
| Q3 2021 | 2021-09-30 | $10.3M | $6.4M | +166.48% |
| Q2 2021 | 2021-06-30 | $9.7M | $9.2M | +1876.83% |
| Q1 2021 | 2021-03-31 | $8.1M | $7.5M | +1154.33% |
| Q4 2020 | 2020-12-31 | $4.4M | — | — |
| Q3 2020 | 2020-09-30 | $3.9M | $3.3M | +547.65% |
| Q2 2020 | 2020-06-30 | $492,000 | −$949,000 | −65.86% |
| Q1 2020 | 2020-03-31 | $646,000 | — | — |
| Q3 2019 | 2019-09-30 | $596,000 | — | — |
| Q2 2019 | 2019-06-30 | $1.4M | — | — |
Kalaris Therapeutics stock-based compensation trends
Over the last five fiscal years, Kalaris Therapeutics's stock-based compensation decreased from $9.4M to $1.9M, a change of −$7.5M. The latest reported quarter, Q2 2026, shows $644,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kalaris Therapeutics source filings ↗